Match Document Document Title
5369015 Method for producing an angiotensin converting enzyme inhibitor-containing composition  
Disclosed is a method for producing an angiotensin converting enzyme inhibitor composition from natural materials, which composition is of use as an antihypertensive drug or diet. The method...
5364841 Treatment of obesity and essential hypertension and related disorders  
The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.
5358934 Materials and methods for control of pests  
The subject invention concerns novel peptides which have the property of interfering with the biosynthesis of the enzyme trypsin. This property enables the use of these peptides to, for example,...
5348943 Cosmetic and skin treatment compositions  
Methods and compositions for (a) improving and/or maintaining the health of skin, and (b) increasing subcutaneous fat in warm-blooded animals are disclosed. The methods utilize an effective amount...
5340817 Method of treating tumors with anti-tumor effective camptothecin compounds  
A camptothecin analog having the structure shown below: ##STR1## where Z is H or C 1 -8 alkyl and R is NO 2 , NH 2 , N 3 , hydrogen, halogen, COOH, OH, O-C 1 -3 alkyl, SH, S-C 1 -3 alkyl, CN, CH 2 ...
5338664 Assay for detection of bacterial iron transport inhibitors  
The present invention relates to a method for identifying a TonB inhibitor in a test sample comprising: (a) growing a TonB + microorganism in the presence of the test sample and a lethal agent,...
5338726 Endothelin converting enzyme inhibitors  
Compounds are disclosed which inhibit endothelin converting enzyme. These compounds are useful for treating hypertension, congestive heart failure, myocardial infarction, reperfusion injury,...
5338668 Opioid peptides derived from wheat proteins  
Disclosed are opioid peptides recovered from hydrolysates of wheat proteins with an acid protease and further a neutral or alkaline protease. Of those peptides, the structure of four opioid...
5326751 Enkephalin analogs  
A new class of opioid receptor analogs is described based on an alanine substitution in the three position in the enkephalin analog DPDPE. The alanine-substituted analogs show increased selectivity...
5317014 Peptides and pseudopeptides derived from tachykinin  
A compound of formula (I): ##STR1## in which: R 1 and R 2 , which are identical or different, represent hydrogen, or alkyl, cycloalkyl or benzyl, B represents a residue of an aromatic amino...
5312811 Peptide derivatives and antidemetia agents  
A novel peptide derivative having the formula: ##STR1## wherein A between Pro and Q 2 is Arg or Lys: Q 1 is pGlu or H; Q 2 is --Gly--OH or OH; Y 1 is H or --CO--T and Y 2 is OH or T; wherein T...
5312812 Pharmaceutical compositions comprising novel oligopeptides exhibiting selective inhibiting effect upon the proliferation of hemopoietic cells  
The present invention relates to novel peptides of formulae Xaa Glu Asp Cys Lys (SEQ I.D. No: 1), and Glu Asp Cys Lys ...
5298491 Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present  
Derivatives of biologically active molecules containing a primary amine group and a hydroxylated nucleus, and their addition salts with mineral or organic acids, having general formula I: ...
5298493 Compound for use in dietetics, reanimation and therapeutics containing protein fractions based on three types of minipeptides  
Methods of treating patients with new compositions intended for use in dietetics, reanimation and therapeutics are provided. The new compositions contain a protein fraction based on three types of...
5298490 Tetra and penta-peptides useful in regulating the immune system  
Tetrapeptides and pentapeptides are disclosed which are capable of regulating the function of cells of the mammalian immune system. Also provided are pharmaceutical compositions containing the...
5284876 Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents  
This invention pertains to a method for treating a subject for Tardive Dyskinesia by administering a dopaminergic agent to the subject such that the dopaminergic agent enters the brain or by...
5284834 Adenosine functionalized congeners as cardiovascular treating agents for animals and methods for using same  
This invention comprises a series of N 6 -substituted adenosine analogues bearing functionalized chains for the covalent attachment to probes or solid supports. In these compounds coronary...
5272151 Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances  
The present invention concerns aminoacyl and oligopeptidyl derivatives of allopurinol (1,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one) of general formula (I), and related salts with ##STR1##...
5270302 Derivatives of tetrapeptides as CCK agonists  
Selective and potent Type-A CCK receptor agonists of formula (I): X--Y--Z--Q (I) or a pharmaceutically acceptable salt thereof, wherein, X is...
5268358 PDGF receptor blocking peptides  
Methods and compositions are provided for treating several acute disease states associated with smooth muscle cell proliferation as well as the chronic process of atherogenesis utilizing...
5260272 Polyanionic polyamino acid inhibitors of mineral deposition and their synthesis  
Polypeptides of the formula poly (X) m (Y) n , wherein X is selected from the group consisting of aspartate, glutamate, glutamine, asparagine, mixtures and block polymers thereof, Y is...
5260276 Linear and monocyclic endothelin antagonists  
Novel linear and monocyclic antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling...
5252558 Pentapeptide having specific inhibiting effect on epidermal cell proliferation, the salts thereof, pharmaceutical compositions comprising the same and a process for the preparation of the pentapeptide and the pharmaceutical compositions  
The present invention relates to novel pentapeptide of formula Xaa Glu Asp Ser Gly (SEQ ID NO: 1) wherein Xaa is pyro-alpha-aminoadipic acid, having...
5250516 Bioelastomeric materials suitable for the protection of burn areas or the protection of wound repair sites from the occurrence of adhesions  
An elastomeric material, capable of reversibly contracting and relaxing by an inverse temperature transition, in a form suitable for use as a protective layer between a mammalian repair site and a...
5248667 Method of treating psoriasis using synthetic peptide compositions  
Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in...
5246920 Treatment of hyperprolactinemia  
A method for the treatment of hypersecretion of prolactin in a patient which comprises co-administration of an effective amount of a growth hormone releasing compound and GHRP-6 or an analog thereof.
5242904 Peptide boronic acid inhibitors of trypsin-like proteases  
Peptides comprising C-terminal boronic acid derivatives of lysine, ornithine, and arginine, homoarginine and corresponding isothiouronium analogs thereof, are reversible inhibitors of trypsin-like...
5238921 Oligopeptide, angiotensin converting enzyme inhibitors, hypotensive agent, and method for treatment of hypertension  
L-Tyr-L-Val, L-Leu-L-Tyr, L-Leu-L-Pro, L-Phe-L-Tyr, L-Tyr-L-Arg and its acid addition salts, L-Leu-L-Ser-L-Pro, L-Leu-L-Gln-L-Pro, L-Phe-L-Leu-L-Pro, L-Leu-L-Leu-L-Pro, L-Leu-L-Asn-L-Pro,...
5227154 Phosphopeptides for the treatment of dental calculus  
A method of inhibiting dental calculus by applying to the teeth an oral composition containing a dental calculus inhibiting amount of one or more of the phosphopeptides SEQ.ID NO:1 to SEQ.ID NO:9,...
5225205 Pharmaceutical composition in the form of microparticles  
A method for preparing a pharmaceutical composition in the form of microparticles, the composition thus obtained and its use for preparing injectable suspensions.
5223485 Anaphylatoxin-receptor ligands  
Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q-T are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease...
5223487 Peptides as antiallergic agents  
The following oligopeptides containing -Asp-Gly- or -Asp-Ser- are synthesized: H-Asp-Gly-Lys-OH H-Ser-Asp-Gly-Lys-OH H-Asp-Ser-Asp-Gly-Lys-OH H-Ala-Asp-Ser-Asp-Gly-Lys-OH The...
5221665 N-substituted amides  
N-substituted amides which inhibit hydrolysis of elastin, are described, which compounds are tri-and di- fluoromethyl ketone amide and non-naturally occurring n-substituted amino acids derivatives.
5215964 Peptides useful in regulating the immune and nervous systems  
Pentapeptides are disclosed which are capable of regulating the function of cells of the mammalian immune and/or nervous system. Also provided are pharmaceutical compositions containing the...
5214032 GHL-CU pharmaceutical compositions and compounds  
Methods and compositions for (a) stimulating the growth of hair in warm-blooded animals, (b) increasing subcutaneous fat in warm-blooded animals, and (c) increasing the density of hair follicles in...
5212154 Preparation for treating complications in diabetes  
Preparation for preventing or combating complications in diabetes, characterized in that it comprises: (a) insulin or a salt or complex thereof, and (b) a peptide of the general formula I: ...
5212157 Enzyme inhibitors  
Disclosed herein are peptide derivatives which inhibit the activity of human immunodeficiency virus (HIV) protease. The peptide derivatives can be represented by general formula R 1 --R 2 --Y--R...
5200394 Derivatives of type A and B synergimycins  
The invention synergimicin derivatives having the general formula: Z--X--R, in which Z is a type A or type B synergimycin radical linked by its reactive carbonyl position, through a branch X, where...
5190921 Amino acids and peptides having a modified tyrosine residue, their preparation and their application as medicaments  
These compounds are represented by formula (I), in which each of R 1 R 2 =H, C 1 -C 8 alkyl, C 3 -C 7 cycloalkyl, or aromatic; (when R 1 =H, R 2 can be an amine function-protecting radical,...
5190922 Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands  
Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states....
5189018 Method for reduction of central nervous system (CNS) edema resulting from head and spinal cord trauma  
A method for reducing the rise in intracranial pressure accompanying head trauma includes the steps of significantly reducing the mean trauma induced increase in blood brain barrier permeability by...
5187167 Pharmaceutical compositions comprising quinazolin-4-one derivatives  
A quinazoline of the formula:- ##STR1## wherein R 1 is alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, aryloxy, arylalkyl, halogeno, hydroxy, mercapto, pyridylthio, pyrimidinylthio,...
5185147 Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus  
Polypeptides in the size range 6-11 amino acids from discrete regions of the human immunodeficiency virus p17 protein are immunogenic and form the basis for diagnosis and therapy of HIV-related...
5182264 Angiotensin II receptor blockers as antiglaucoma agents  
A method and composition for reducing and/or controlling elevated intraocular pressure, especially the elevated intraocular pressure associated with glaucoma, are disclosed in which an angiotensin...
RE34165 Potent thymopentin analogs  
Immunoregulating peptides are disclosed which are more potent than thymopentin or splenin and are useful for their effects on the immune system, especially the treatment of thymic deficiencies.
5180722 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs  
A camptothecin analog having the structure shown below: ##STR1## where Z is H or C 1 -8 alkyl and R is NO 2 , NH 2 , N 3 , hydrogen, halogen, COOH, OH, O--C 1 -3 alkyl, SH, S--C 1 -3 alkyl, CN, CH...
5180712 Petide antidementia and nootropic agents  
A peptide having one of the following formulae (I), (II), (III) and (IV): ##STR1## or its functional derivatives, and a pharmaceutically acceptable salt thereof are disclosed. These peptides have a...
5169833 Substituted cyclic pentapeptides  
The present invention provides substituted cyclic pentapeptide compounds of general Formula I: ##STR1## and the pharmaceutically-acceptable slats, esters and amides thereof, which are useful for...
5166136 Spirolactam containing peptides  
These are described spirolactam derivatives of formulae (Ia) and (Ib) ##STR1## wherein R represents a hydrogen atom or a conventional nitrogen protecting group; R 1 represents a hydrogen atom...
5164367 Method of using copper(II) containing compounds to accelerate wound healing  
Methods for the use of compositions of copper(II) containing compounds to accelerate healing of wounds in warm-blooded animals. The methods include systemic loading of copper(II) to accelerate the...